Scarlett L.

Established in 2015, Trautec is dedicated to the development and production of recombinant collagen based (SRHC) biomaterials for mainly medical and cosmetics industries. SRHC produced by biosynthesis is non-animal produced collagen. As the pioneer of the industry, Trautec operates the full value chain from R&D, manufacturing, to distribution, by holding multiple intellectual property rights in the development of recombinant collagen, and owning its production plant located in Jiangsu, China. The market of functional skincare, which offers specific functions to skin, is growing significantly as more and more consumers are looking for effective solutions to their skin problems. The needs for recombinant collagen are expanding because of its stability and effectiveness as well as wide application to medical, healthcare and cosmetics fields. In 2022, the Shiseido Beauty Innovation Fund invested into Trautec and form a full strategic partnership between Shiseido and Trautec to work together in all areas including product search and development, raw material supply, and sales channels to exploration of new areas in functional skincare. In 2023, the B-round financing has been successfully signed. The round was jointly led by L Catterton, the world’s largest consumer-focused private equity firm under LVMH. This round of financing will mainly be used for industrialization promotion, innovative technology research and development, and overseas market expansion. Trautec continues to expand the application of SRHC in high-end fields including medicine, medical regeneration, and aesthetics, and occupy the forefront of the industry.